Mutant pore
AssigneeOxford Nanopore Technologies PLC
InventorsLakmal Nishantha Jayasinghe, Mark John Bruce, Luke McNeill, Ramiz Iqbal Nathani, Pratik Raj Singh, Neil Roger Wood, Stephen Robert Young
Life of this patent
Estimating the term…
Abstract
The invention relates to mutant forms of lysenin. The invention also relates to analyte characterisation using the mutant forms of lysenin.
Claims14
An apparatus comprising a transmembrane protein pore inserted into an in vitro membrane, wherein the transmembrane protein pore comprises at least one mutant lysenin monomer comprising a variant of the sequence set forth in SEQ ID NO:
- 2, wherein the variant comprises the S49K/R/L amino acid substitution.
An apparatus for characterizing a target analyte, the apparatus comprising a plurality of mutant lysenin monomers, wherein each mutant lysenin monomer comprises a variant of the sequence set forth in SEQ ID NO:
- 2, wherein the variant comprises the S49K/R/L amino acid substitution, and wherein the plurality of mutant lysenin monomers is inserted into a plurality of in vitro membranes.
A transmembrane protein pore comprising at least one mutant lysenin monomer, wherein the at least one mutant lysenin monomer comprises the amino acid sequence of SEQ ID NO:
- 2 having the S49K/R/L amino acid substitution.
An apparatus produced by a method comprising:
- (i) obtaining a transmembrane protein pore comprising at least one mutant lysenin monomer, wherein the at least one mutant lysenin monomer comprises the amino acid sequence of SEQ ID NO:
- 2 having the S49K/R/L amino acid substitution and (ii) contacting the pore with an in vitro membrane such that the pore is inserted into the in vitro in vitro membrane.
Dependencies are inferred from the claim text.